Your session is about to expire
← Back to Search
Glasdegib for Graft-versus-Host Disease
Study Summary
This trial will study whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease, as well as the safety of glasdegib in treating patients with chronic graft-versus-host disease.
- Chronic Graft-versus-Host Disease
- Plantar Fasciitis
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 14 Patients • NCT04842604Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You experience moderate to severe muscle cramps, or mild muscle cramps that happen at least once a week.You have a known problem with one or more of your organs.You need to use oxygen to help you breathe.Your overall physical ability and health is below 70%.You have experienced bad reactions to glasdegib, sonidegib, or vismodegib in the past.You have visible signs of skin involvement (score of 2 or higher) or joint and fascia involvement (score of 1 or higher).You have less than 6 months to live.You had surgery to remove all of your cancer, or your cancer is not expected to affect your survival during the study.You have been diagnosed with a condition called chronic graft-versus-host disease (cGVHD) that causes sclerosis or fasciitis.
- Group 1: Treatment (glasdegib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many individuals are being researched in this trial?
"The recruitment window for this trial has been closed. The research was first advertised on December 3rd, 2019 and the last update happened June 13th 2022. If you are looking to participate in other studies, there are 200 trials involving plantar fasciitis patients and 8 clinical studies with Glasdegib currently accepting participants."
Is this investigation unprecedented in its trial format?
"Currently, Glasdegib has 8 ongoing clinical trials across 19 cities and 12 countries. In 2014, Pfizer initiated the first trial of its kind with 48 participants who completed Phase 1 drug approval. Since then, 15 studies have concluded successfully."
Are there any auxiliary research studies that have utilized Glasdegib?
"Presently, 8 clinical trials for Glasdegib are underway with 3 in Phase 3. While Houston is a hub of activity, there are 106 facilities across the US utilizing this drug to study patient outcomes."
Is the enrollment process for this trial still open?
"At this juncture, this experiment is not enrolling candidates. It was initially posted on December 3rd 2019 and the last changes were made to it on June 13th 2022. For those who are interested in other available clinical trials, there are 200 for plantar fasciitis and 8 related to Glasdegib that require participants."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger